A Post Marketing Surveillance Study To Determine The Safety, Tolerability And Effectiveness Of Doxazosin Mesylate GITS Among Filipino Adult Males With Benign Prostatic Hyperplasia (BPH)

NCT01003886 COMPLETED Results posted

This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.

Details

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status	COMPLETED
Enrolment	989
Start date	2009-05
Completion	2011-01

Conditions

• Prostatic Hyperplasia

Interventions

• Doxazosin mesylate GITS

Primary outcomes

• Number of Participants With Adverse Events (AEs) — Baseline up to Week 13 (7 days after last dose)
  Any untoward medical occurrence in a participant who received study drug was considered an AE, without regard to possibility of causal relationship.

Countries

Philippines